Multicenter, Double-Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine/Cisplatin Plus Bevacizumab or Placebo in Patients With Malignant Mesothelioma

PURPOSE: Gemcitabine plus cisplatin is active in malignant mesothelioma (MM), although single-arm phase II trials have reported variable outcomes. Vascular endothelial growth factor (VEGF) inhibitors have activity against MM in preclinical models. We added the anti-VEGF antibody bevacizumab to gemci...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Kindler, Hedy L., Karrison, Theodore G., Gandara, David R., Lu, Charles, Krug, Lee M., Stevenson, James P., Jänne, Pasi A., Quinn, David I., Koczywas, Marianna N., Brahmer, Julie R., Albain, Kathy S., Taber, David A., Armato, Samuel G., Vogelzang, Nicholas J., Chen, Helen X., Stadler, Walter M., Vokes, Everett E.
Format: Artigo
Langue:Inglês
Publié: American Society of Clinical Oncology 2012
Sujets:
Original Reports
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3397785/
https://ncbi.nlm.nih.gov/pubmed/22665541
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2011.41.5869
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires